Glenmark signs deal with Novartis over distribution in Brazil

pharmafile | June 24, 2019 | News story | Sales and Marketing Brazil, Glenmark, Latin America, Novartis, distribution, pharma 

Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.

Novartis will distribute three of Glenmark’s COPD drugs in Brazil from 1 July 2019.

The Swiss firm will be responsible for promoting, commercialising and distributing Glenmark’s Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium) – all of which treat the symptoms of COPD.

“This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark.

Glenmark receives around 5% of its revenue from Latin America. However Indian generic drugmakers – who are now facing pricing pressures in the US – are increasingly focused on increasing sales in big markets such as Brazil.

Louis Goss

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Novartis announce digital collaboration with HPE

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate …

Latest content